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Abstract
Background: Selecting patients with peritoneal metastases from colorectal cancer (CRCPM) who might benefit
from cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is challenging.
Computed tomography generally underestimates the peritoneal tumor load. Diagnostic laparoscopy is often used
to determine whether patients are amenable for surgery. Magnetic resonance imaging (MRI) has shown to be
accurate in predicting completeness of CRS. The aim of this study is to determine whether MRI can effectively
reduce the need for surgical staging.
Methods: The study is designed as a multicenter randomized controlled trial (RCT) of colorectal cancer patients
who are deemed eligible for CRS-HIPEC after conventional CT staging. Patients are randomly assigned to either MRI
based staging (arm A) or to standard surgical staging with or without laparoscopy (arm B). In arm A, MRI
assessment will determine whether patients are eligible for CRS-HIPEC. In borderline cases, an additional diagnostic
laparoscopy is advised. The primary outcome is the number of unnecessary surgical procedures in both arms
defined as: all surgeries in patients with definitely inoperable disease (PCI > 24) or explorative surgeries in patients
with limited disease (PCI < 15). Secondary outcomes include correlations between surgical findings and MRI
findings, cost-effectiveness, and quality of life (QOL) analysis.
Conclusion: This randomized trial determines whether MRI can effectively replace surgical staging in patients with
CRCPM considered for CRS-HIPEC.
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Background
Peritoneal metastatic disease is the dissemination of can-
cer within the abdominal cavity. It is the second leading
cause of death in patients with colorectal cancer (CRC).
10.6% of CRC patients present with peritoneal metasta-
ses at diagnosis or will develop peritoneal metastases at
a later stage [1]. Selected patients benefit from cytore-
ductive surgery (CRS) followed by hyperthermic intra-
peritoneal chemotherapy (HIPEC). CRS-HIPEC is
potentially curative and has shown to improve median
survival in patients with limited disease [2–4]. Macro-
scopically complete resection of all metastatic lesions is
vital to obtain survival gain [5]. Currently, assessment of
the extent and localization of peritoneal metastases, to
determine whether a complete CRS is feasible, is ultim-
ately performed during laparotomy. Open-close or in-
complete procedures have been reported to occur in 20
to 40% of cases [6–11]. However, best practice would be
to avoid futile, invasive and costly surgical procedures in
patients for whom CRS-HIPEC is not feasible and/or un-
likely to improve survival. Laparoscopic assessment is a
less invasive and effective tool to reduce futile laparoto-
mies [9]. However, tumor mass or adhesions may pre-
vent laparoscopic evaluation of all regions of the
peritoneal cavity. Incomplete laparoscopic staging has
been reported to occur in around 23% of patients [6].
Laparoscopy is considered minimally invasive but a risk
of intraoperative complications and postoperative mor-
bidity presides. Hence, a non-invasive pre-operative tool
is needed to better select patients eligible for CRS-HIPE
C.
CT is the preferred first-line imaging tool for the de-
tection of peritoneal metastases but falls short when
used to assess the total peritoneal tumor burden [12–
16]. Magnetic resonance imaging (MRI), with diffusion-
weighted imaging (DWI), has shown to predict the ex-
tent of disease accurately (sensitivity of 0.80–0.98 and a
specificity 0.85–0.93% [17, 18]) and to be a valuable ad-
junct to decide whether complete cytoreduction can be
achieved [13, 15, 17]. DWI-MRI had also shown to be
superior for detecting liver metastases [19, 20]. However,
research towards the value of MRI for patients with
colorectal peritoneal metastases has been limited to co-
hort studies in a retrospective or observational setting.
Objective
The primary objective of this study is to determine
whether additional preoperative dedicated MRI staging
to can reduce the number of futile (exploratory) surger-
ies in patients with CRC considered for CRS-HIPEC as
compared to the standard of care of CT alone. An un-
necessary surgical procedure is defined as any non-
therapeutic laparotomy or diagnostic laparoscopy in pa-
tients, with exception of patients with borderline oper-
able disease (15<PCI> 24).
Methods/design
This investigator-initiated, multi-center, randomized
controlled trial is performed in Dutch HIPEC centers
since September 2019. The study is conducted according
to the principles of the Declaration of Helsinki and in
accordance with the Medical Research Involving Human
Subjects Act (WMO) and was approved by the medical
ethics committee at the Netherlands Cancer Institute
(date: 13-09-2019; ref. no.: NL70045.031.19) and is retro-
spectively registered in the clinical trials registry of U.S.
National Library of Medicine under NCT04231175
(https://clinicaltrials.gov/ct2/show/NCT04231175). Pa-
tients suspected of having CRC peritoneal metastases
and considered for CRS-HIPEC, are eligible for inclu-
sion. Patients are randomly assigned to one of two diag-
nostic arms towards CRS-HIPEC. A trial flow diagram is
presented in Fig. 1.
Eligibility criteria
In order to be eligible to participate in this study, a sub-
ject must meet all of the following criteria:
– Patients with suspicion of CRCPM and considered
for CRS-HIPEC after CT imaging
– Age ≥ 18 years
– Written and signed informed consent
– Performance status of WHO 0–2
– Able and willing to drink 1 l of pineapple or
blueberry juice (required as a preparatory step for
the dedicated MRI)
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
– Patients with contraindications for MRI
– Patients with clinical contraindications for CRS-
HIPEC, such as but not limited to inadequate organ
or hematological function, significant medical his-
tory, active pregnancy and lactation, or old age
Engbersen et al. BMC Cancer          (2021) 21:464 Page 2 of 8
– Patients with radiological contra-indications for
CRS-HIPEC observed on CT thorax/abdomen
– Patients with concurrent or history of other
malignancy within ≤5 years prior to CRCPM
diagnosis
Patient recruitment and randomization
Eligible patients are identified and informed about the
study by their treating physician at the participating cen-
ter. Patients are included after written informed consent.
Patients are randomly assigned to an experimental arm
(A) or a control arm (B). The random assignment is per-
formed by dedicated medical data managers or a re-
search nurse using specific clinical trial management
software (ALEA clinical, Abcoude, The Netherlands). A
random block randomization is used and stratified per
participating center. Blinding is not possible with this
trial set-up.
Study interventions
Patients in Arm A receive a dedicated 3 T MRI scan,
which includes T2 weighted, T1 weighted, diffusion
weighted and non-enhanced + gadolinium enhanced fat-
suppressed T1 weighted imaging of the pelvis and abdo-
men (and thorax on DWI), as previously described [15].
Patients are asked to drink one liter of pineapple or
blueberry at least 1 h before the MRI scan. This mini-
mizes the signal from the intraluminal content on DWI
and bowel movement, respectively. An antispasmolitic
drug is administered intravenously to optimize bowel
evaluation. The MRI protocol is specified in Table 1.
Based on the findings of the MRI scan, the radiologist
Fig. 1 Flow diagram of DISCO trial
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advises whether patients are to be allocated to one of the
following diagnostic/treatment options:
– CRS-HIPEC is feasible; perform CRS-HIPEC
○ Peritoneal cancer index estimated on MRI
(MRI-PCI) < 15 and no non-peritoneal lesions
(that contra-indicate CRS-HIPEC)
– CRS-HIPEC might be feasible; consider diagnostic
laparoscopy (DLS) to determine whether CRS-HIPE
C is feasible and justifiable
○ MRI-PCI between 15 and 24 and no non-
peritoneal lesions (that contra-indicate CRS-HIPE
C)
– CRS-HIPEC is not feasible; chemotherapy or best
supportive care
○ MRI-PCI > 24 and/or detection of non-
peritoneal lesions (that contra-indicate CRS-HIPE
C)
In the Netherlands, patients are eligible for CRS-HIPE
C if the PCI does not exceed 20 at surgical exploration
[21]. All participating centers perform CRS-HIPEC pro-
cedures under the Dutch HIPEC protocol, as described
by Kuijpers and colleagues [21]. With this policy in
mind, the cut-off points for MRI-assessment have been
determined using preliminary data of the initiating cen-
ter [15]. The MRI-PCI cut-off of 15 ensures targeted use
of DLS and the cut-off of 24 prevents the false omission
of patients for whom CRS-HIPEC is feasible. If a specific
disease localization is found which could contraindicate
CRS-HIPEC, i.e. duodenal involvement, DLS may still be
performed at the discretion of the multidisciplinary team
(MDT). Surgical procedures must be performed within 4
weeks after the MRI.
In arm B, patients undergo the standard diagnostic
work-up followed by a DLS at the discretion of the
MDT, as determined before randomization. For the con-
trol group no study specific guidelines for DLS use have
been determined, centers are expected to continue
implementing DLS according to their own current pol-
icies. The rate of laparoscopy use may therefore vary be-
tween centers.
All patients will be asked to fill in two QOL question-
naires (EORTC-C30 and EQ5D5L) at baseline
(randomization), at 3 months, and 6 months. At 6
months after CRS-HIPEC, all patients undergo a follow-
up of CT, MRI, serum biomarkers (carcinoembryonic
antigen or CEA, cancer antigen 125 or CA 125, and can-
cer antigen 19.9 or CA 19.9), and physical examination
to screen for early disease recurrence in the peritoneum,
liver, or elsewhere. This will also serve as an extra qual-
ity check of diagnostic and surgical outcome. It is ex-
pected that a residual peritoneal or non-peritoneal
metastasis will have become apparent at 6 months on
MRI. If residual disease of early recurrence is observed,
treatment is at the discretion of the local MDT. The trial
schedule is summarized in Table 2.
MRI evaluation
All study MRIs will be evaluated by an abdominal radi-
ologist with experience in DWI of the participating cen-
ter and by experienced abdominal radiologists of the
trial-initiating center with extensive experience with the
study protocol dedicated to peritoneal metastasis evalu-
ation, independently. The findings of the radiologists
then will be shared and discussed before the MDT meet-
ing. In case of discrepant findings, the findings from the
trial-initiating center’s radiologist are leading. Radiolo-
gists of the participating centers will undergo training in
the study specific MRI evaluations, followed by on-the-
job training with continued feedback of the trial-
initiating center.
Criteria used to establish the presence of peritoneal
disease on MRI include the presence of high signal on
DWI with a corresponding soft tissue lesion of periton-
eal thickening on T2 weighted or contrast enhanced T1
weighted images, as previously described [15].
Table 1 Dedicated MRI protocol for peritoneal surface malignancies
Diffusion weighted T2 weighted T1 weighted
Pre-contrast Post-contrast Post contrast
Pulse sequence SS EPI b0, b1000 SS TSE SS TSE mDixon 3D FFE mDixon 3D FFE mDixon 3D FFE
Imaging plane Transversal Transversal Coronal Transversal Transversal Coronal
Anatomical area Thorax, abdomen, pelvis Abdomino-pelvic Thorax, abdomen, pelvis Abdomino-pelvic Abdomino-pelvic Abdomino-pelvic
Respiration Free-breathing Free-breathing Free-breathing Free-breathing Free-breathing Free-breathing
Fat supression SPIR – – SPAIR SPAIR SPAIR
TR/TE (ms) Shortest 1500/87 1500/87 Shortest Shortest Shortest
NSA 1 1 1 1 1 1
Slice thickness (mm) 5 4 6 5 5 5
Gap (mm) 0.5 0.4 0.6 −2.5 −2.5 −2.5
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Data collection
Basic clinical information is collected, including pa-
tient history, primary tumor location, tumor histology,
previous surgical procedures, chemotherapy and/or
radiotherapy history, and serum biomarkers. For each
abdominal assessment preformed to assess eligibility
for CRS-HIPEC (CT, MRI, laparoscopy, and laparot-
omy), a case report form (CRF) is filled out including
the same parameters for each assessment, where ap-
propriate. These parameters include the PCI, the
presence of organ infiltration, the presence and pat-
tern of miliary spread, presence of non-PM (such as
liver and lymph node metastases) and diaphragmatic
involvement. Parameters specific to radiological as-
sessments (CT, MRI) include scan quality, scan com-
pletion, presence of extra abdominal metastases
(retroperitoneum, chest), and presence of pleural effu-
sion. For each radiological finding, the reader will in-
dicate whether the feature is present (yes/no) and
how certain he or she is of that decision (not certain/
quite certain/ certain). Parameters specific to surgical
assessment include extent of adhesiolysis and accessi-
bility. Surgical findings are considered the reference
standard. No confidence level will be applied to those
parameters. For the laparotomies that proceed to CRS-
HIPEC, a separate CRF registers which resections, exci-
sions, and/or extirpations have been performed, as well as
the completeness of cytoreduction (resection status). All
data is collected by the local research team, consisting of
at least one radiologist, one surgeon, and a research nurse
and/or medical data manager. The pseudo-anonymized
data is entered and stored with the same clinical trial
management software used for randomization (ALEA
clinical, Abcoude, The Netherlands) in an ISO 27001 cer-
tified hosting facility in the Netherlands.
Outcome measures
The primary outcome measure is a composite endpoint
of futile surgical explorations. A futile surgical explor-
ation is defined as: all surgeries in patients with defin-
itely inoperable disease (PCI > 24) or explorative
surgeries in patients with limited disease (PCI < 15).
The secondary outcomes include:
– number of incomplete CRS-HIPECs (R2a/ R2b/
open-close),
– number of residual disease events or early
recurrences at 6 months after a complete resection
at CRS-HIPEC,
– number of non-peritoneal metastases,
– diagnostic performance of MRI and diagnostic
laparoscopy to predict whether complete CRS-HIPE
C is feasible,
– correlations between MRI findings and surgical
findings,
– incremental cost-effectiveness,
– Patient reported QOL between study arms.
Costs and patient reported quality of life measures
Direct medical costs include both the immediate medical
costs such as diagnostic tests and initial treatments (in-
cluding side-effects), as well as later treatments. Direct
costs incorporated in the current study include costs of
standard diagnostic staging (CT+/−laparoscopy), CRS-
HIPEC and treatment of recurrences, follow-up visits
and palliative care. Resource use data will be collected
from the hospital’s administrative database. Where ap-
propriate, Dutch guidelines for costing studies will be
used in applying tariffs to units of resource use [22].
For the health related quality of life (QoL), the
EORTC-C30 questionnaire will be used [23]. For cost-
Table 2 Schedule of enrolment, interventions, and assessments
STUDY PERIOD
Enrolment Allocation Diagnostic Work-up Treatment Follow-up










QUALY forms X X X
X applicable to all patients; A applicable to those allocated to experimental Arm A; B applicable to those allocated to control arm B
a only applicable if called for by previous diagnostics
b only applicable if R1 resection was achieved at CRS-HIPEC
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effectiveness purposes, utilities will be measured, in
order to derive quality-adjusted-life-years (QALYs). The
utilities will reflect the preferences of society for length
of life versus quality of life. The utilities will be derived
from the trial by means of the EQ5D5L questionnaire
[24]. The questionnaires are given to patients at baseline
(T0), 3 months after the diagnostic staging and treat-
ment (T1), and after 6 months (T2).
Statistical analysis
Sample size calculation
Power calculations are based on an expected reduction
of futile surgical explorations from 30 to 15% by MRI
staging. With a two-sample two-sided test of binomial
proportions and an α of 0.05, a ß of 0.20, and an ex-
pected drop-out rate of 20%, 272 patients are to be in-
cluded in total.
Data analysis
The observed difference in preventable surgical explora-
tions between trial arms will be tested with a McNemar’s
chi-squared test, as well as the difference in incomplete
CRS-HIPECs, non-peritoneal findings before surgery,
and early recurrences or residual disease visible at first
follow-up (6 months). Progression free survival will be
analyzed by binomial logical regression analysis. Progres-
sion free survival is defined as the time in days from
complete CRS-HIPEC to recurrence or progression of
disease as determined by the multidisciplinary team
meeting or death of any cause. Correlations between
MRI staging and surgical staging will be evaluated by
intraclass correlation coefficients (ICC), Cohen’s kappa,
and Cohen’s weighted kappa, where appropriate. Diag-
nostic performance of MRI and surgical staging to pre-
dict complete CRS will be compared by confusion
matrix analysis and receiver operator characteristic ana-
lysis. Differences in predictive values will be tested with
McNemar’s test and the DeLong test, where appropriate.
Cost-effectiveness analysis
A cost-effectiveness Analysis will be performed with in-
cremental costs per Quality Adjusted Life Year gained as
outcome for patients with PM undergoing MRI versus
usual diagnostic work-up for selection for CRS-HIPEC.
A Markov model will be constructed, a lifelong time
horizon with 3 months cycle length will be used, and a
societal perspective from the Netherlands will be
adopted. Future costs and effects will be discounted to
their present value by a rate of 4 and 1.5% per year re-
spectively, according to Dutch guidelines [25]. The re-
sults of the probabilistic sensitivity analysis will be
illustrated in a cost-effectiveness plane, and cost-
effectiveness acceptability curves (CEACs) will show de-
cision uncertainty. CEACs show the probability that a
pathway has the highest net monetary benefit, and thus
is deemed cost-effective, for a range of Willingness to
Pay values for one additional QALY, also referred as the
ceiling ratio. In this analysis, we will use the Dutch (in-
formal) ceiling ratio of €80,000 per QALY [26].
Discussion
Selected CRC patients with limited PM can benefit from
CRS-HIPEC with a chance of a significantly prolonged
survival and in some cases even cure. Currently, the final
clinical decision of whether complete resection at CRS-
HIPEC is feasible is often determined during surgery.
Rehabilitation from open-close surgery is not in the best
interest of a palliative patient and may delay palliative
treatment or inclusion in trials. Two trials are ongoing
in the Netherlands exploring novel palliative strategies
for patients with extensive CRCPM, namely the use of
concomitant intraperitoneal and systemic chemotherapy
(INTERACT) and repetitive electrostatic pressurized in-
traperitoneal aerosol chemotherapy with oxaliplatin
(ePIPAC) [27, 28].
Twenty-three percent of candidates for the PRODIGE-
7 trial were excluded at laparotomy due to the extent of
PM, liver metastases or non-resectable disease [11].
Other studies have reported incomplete CRS rates of
around 20–40%, when selecting patients suitable for
CRS-HIPEC with CT [6, 7, 10]. To help reduce the in-
complete CRS rate, laparoscopy can be used to better as-
sess the feasibility of complete cytoreduction.
Improvements of 7–15% in the number of incomplete
CRS-HIPECs have been reported after clinical imple-
mentation of laparoscopy [10, 29]. A cohort study
researching the clinical impact of implementing DLS
into the diagnostic work-up reported that in 35.2% not
all abdominopelvic regions were visualized at DLS [10].
PPVs for predicting complete cytoreduction have been
reported of 0.63–0.97 with DLS [6, 8–10, 30]. Sensitiv-
ities and specificities of 0.80–0.98 and 0.85–0.93 have
been reported with use of MRI at region-wise analysis in
two cohort studies of 27 and 60 patients [17, 18], from
with a PPV of 0.90 could be achieved for predicting an
operable extent of disease [17]. This was in concordance
with the findings of Van’t Sant and colleagues who re-
ported a PPV of 0.89 finding an operable extent of dis-
ease in a cohort study of 49 patients [15]. MRI can give
information about peritoneal involvement in all regions,
even those that might not be accessible with DLS due to
adhesions, tumor, or anatomical limitations (such as dia-
phragmatic dorsal area and gastrosplenic ligament). MRI
staging may therefore aid operative planning. MRI is fur-
thermore non-invasive and much less costly than a diag-
nostic laparoscopy.
A limitation of MRI in the work up of CRC patients
with PM is the lack of histopathological proof of
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identified lesions. However, we expect that in most cases
patients will have lesions that are accessible by biopsy or
present with proven PM during a previous surgical pro-
cedure. If this is not the case, a DLS may still be neces-
sary. Patients with severe claustrophobia as well as
patients with metal implants non-compatible with MRI
are not eligible for MRI assessment. Policy differences
between hospitals may lead to differences in laparoscopy
rates and open-close rates in the control arm. Assuming
that the rate of DLS is inversely related to the incom-
plete and open-close rate, the potential benefit of add-
itional MRI staging could nonetheless become apparent.
Furthermore, the benefit of Oxaliplatin-based HIPEC in
the combined CRS-HIPEC procedure has recently come
under debate following the results of the PRODIGE-7
trial [11]. However, this study reinforced the notion that
complete cytoreduction is the most determinant factor
of survival, a finding that underlines how important it is
to safely and effectively select those patients for whom a
complete CRS is feasible. Therefor our trial would con-
tinue to be relevant to select patients for CRS, alone or
CRS in combination with any perioperative therapy.
If MRI staging effectively reduces the number of surgi-
cal explorations in CRS-HIPEC candidates, patients with
PM from CRC will be exposed to a less invasive and
more effective triaging system.
Abbreviations
CA: 125 cancer antigen 125; CA: 19.9 cancer antigen 19.9;
CEA: Carcinoembryonic antigen; CEAC: Cost-effectiveness acceptability curve;
CRC: Colorectal cancer; CRCPM: Colorectal peritoneal metastases;
CRS: Cytoreductive surgery; CT: Computed tomography; DLS: Diagnostic
laparoscopy; DWI: Diffusion weighted imaging; ePIPAC: Electrostatic
pressurized intraperitoneal aerosol chemotherapy; HIPEC: Hyperthermic
intraperitoneal chemotherapy; ICC: Intraclass correlation coefficient;
MDT: Multidisciplinary team; MRI: Magnetic resonance imaging;
PCI: Peritoneal cancer index; PM: Peritoneal metastases; RCT: Randomized
controlled trial; WHO: World health organization; QOL: Quality of life;




Trial set-up ME, ML, NK, VR; Trial coordination: ME, CR, JN, ML, EvdH, EM, PdR;
Manuscript writing; ME, ML; Manuscript Review and editing: AA, IdH, JN, VR,
CR, DL, EvdH, DB, MW, MdV, EM, ABK, SvK, PR, RBT, NK; All authors have read
and approved the manuscript.
Funding
Funding is provided by the Dutch organization for health research and
healthcare innovation, ZonMw (The Hague, NL) (project number: 852002003).
The funder’s role is limited to grant application review and approval.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participle
Patients will need to provide written informed consent to participate with
this study. The study has been approved by the Medical Ethics Committee of




The authors declare that they have no competing interests.
Author details
1Department of Radiology, Netherlands Cancer Institute, Plesmanlaan 121,
1066 CX Amsterdam, The Netherlands. 2GROW, School for Oncology and
Developmental Biology, Maastricht University Medical Center, Maastricht, The
Netherlands. 3Department of Surgery, Netherlands Cancer Institute,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. 4Department of
Radiology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The
Netherlands. 5Department of Surgery, Catharina Hospital, Michelangelolaan 2,
5623 EJ Eindhoven, The Netherlands. 6Department of Psychosocial research
and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands. 7Department Health Technology and Services
Research (HTSR), University of Twente, Drienerlolaan 5, Enschede, The
Netherlands. 8Department of Radiology, St. Antonius Hospital, Soestwetering
1, 3543 AZ Utrecht, The Netherlands. 9Department of Surgery, St. Antonius
Hospital, Soestwetering 1, 3543 AZ Utrecht, The Netherlands. 10Department
of Radiology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015
GD Rotterdam, The Netherlands. 11Department of Surgery, Erasmus
University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The
Netherlands. 12Department of Radiology, Radboud University Medical Center,
P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. 13Department of Surgery,
Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, the
Netherlands.
Received: 14 September 2020 Accepted: 11 April 2021
References
1. Kerscher A, Chua T, Gasser M, Maeder U, Kunzmann V, Isbert C, et al. Impact
of peritoneal carcinomatosis in the disease history of colorectal cancer
management: a longitudinal experience of 2406 patients over two decades.
Br J Cancer. 2013;108(7):1432.
2. De Cuba E, Kwakman R, Knol D, Bonjer H, Meijer G, Te Velde E.
Cytoreductive surgery and HIPEC for peritoneal metastases combined with
curative treatment of colorectal liver metastases: systematic review of all
literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;
39(4):321–7.
3. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al.
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia
with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin
Oncol. 2009;27(5):681–5. https://doi.org/10.1200/JCO.2008.19.7160.
4. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III.
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion
versus systemic chemotherapy alone for colorectal peritoneal
carcinomatosis. Cancer. 2010;116(16):3756–62. https://doi.org/10.1002/cncr.2
5116.
5. Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for
cytoreductive surgery and HIPEC for the treatment of peritoneal metastases
from colorectal cancer. Cancer Manag Res. 2017;9:259–66. https://doi.org/1
0.2147/CMAR.S119569.
6. Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for
peritoneal carcinomatosis. Br J Surg. 2013;100(2):285–92.
7. van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B,
Nienhuijs SW, et al. Peritoneal cancer patients not suitable for cytoreductive
surgery and HIPEC during explorative surgery: risk factors, treatment
options, and prognosis. Ann Surg Oncol. 2015;22(4):1236–42. https://doi.
org/10.1245/s10434-014-4148-x.
Engbersen et al. BMC Cancer          (2021) 21:464 Page 7 of 8
8. Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D. The role of laparoscopy
to evaluate candidates for complete cytoreduction of peritoneal
carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg
Oncol. 2005;31(5):540–3. https://doi.org/10.1016/j.ejso.2005.01.009.
9. Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM. Laparoscopy is Safe and
Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive
Surgery. Ann Surg Oncol. 2016;23(5):1461–7.
10. Hentzen J, Constansia RDN, Been LB, Hoogwater FJH, van Ginkel RJ, van
Dam GM, et al. Diagnostic laparoscopy as a selection tool for patients with
colorectal peritoneal metastases to prevent a non-therapeutic laparotomy
during Cytoreductive surgery. Ann Surg Oncol. 2020;27(4):1084–93. https://
doi.org/10.1245/s10434-019-07957-w.
11. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive
surgery plus hyperthermic intraperitoneal chemotherapy versus
cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE
7): a multicentre, randomised, open-label, phase 3 trial. The Lancet
Oncology. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)3
0599-4.
12. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, et al.
Accuracy and clinical relevance of computed tomography scan
interpretation of peritoneal cancer index in colorectal cancer peritoneal
carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70.
https://doi.org/10.1002/jso.21601.
13. Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the
peritoneal Cancer index (PCI) preoperatively in patients being considered
for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708–15.
https://doi.org/10.1245/s10434-014-4041-7.
14. Duhr CD, Kenn W, Kickuth R, Kerscher AG, Germer C-T, Hahn D, et al.
Optimizing of preoperative computed tomography for diagnosis in patients
with peritoneal carcinomatosis. World J Surg Oncol. 2011;9(1):171.
15. van’t Sant I, van Eden WJ, Engbersen MP, Kok NFM, Woensdregt K,
Lambregts DMJ, et al. Diffusion-weighted MRI assessment of the peritoneal
cancer index before cytoreductive surgery. Br J Surg. 2019;106(4):491–8.
16. Koh FHX, Tan KK, Teo LLS, Ang BWL, Thian YL. Prospective comparison
between magnetic resonance imaging and computed tomography in
colorectal cancer staging. ANZ J Surg. 2018;88(6):E498–502. https://doi.org/1
0.1111/ans.14138.
17. Dresen RC, De Vuysere S, De Keyzer F, Van Cutsem E, Prenen H,
Vanslembrouck R, et al. Whole-body diffusion-weighted MRI for operability
assessment in patients with colorectal cancer and peritoneal metastases.
Cancer Imaging. 2019;19(1):1. https://doi.org/10.1186/s40644-018-0187-z.
18. Zhang H, Dai W, Fu C, Yan X, Stemmer A, Tong T, et al. Diagnostic value of
whole-body MRI with diffusion-weighted sequence for detection of
peritoneal metastases in colorectal malignancy. Cancer Biol Med. 2018;15(2):
165–70.
19. Kim HJ, Lee SS, Byun JH, Kim JC, Yu CS, Park SH, et al. Incremental value of
liver MR imaging in patients with potentially curable colorectal hepatic
metastasis detected at CT: a prospective comparison of diffusion-weighted
imaging, gadoxetic acid–enhanced MR imaging, and a combination of both
MR techniques. Radiology. 2014;274(3):712–22.
20. Achiam MP, Løgager VB, Skjoldbye B, Møller JM, Lorenzen T, Rasmussen VL,
et al. Preoperative CT versus diffusion weighted magnetic resonance
imaging of the liver in patients with rectal cancer; a prospective
randomized trial. Peer J. 2016;4:e1532.
21. Kuijpers AM, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van
Ramshorst B, et al. Implementation of a standardized HIPEC protocol
improves outcome for peritoneal malignancy. World J Surg. 2015;39(2):453–
60. https://doi.org/10.1007/s00268-014-2801-y.
22. Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van RL.
Update of the Dutch manual for costing studies in health care. PLoS One.
2017;12(11):e0187477. https://doi.org/10.1371/journal.pone.0187477.
23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.
The European Organization for Research and Treatment of Cancer QLQ-C30:
a quality-of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst. 1993;85(5):365–76.
24. Oppe M, Devlin NJ, Szende A. EQ-5D value sets: inventory, comparative
review and user guide: springer; 2007.
25. Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan SJD,
the Netherlands: Zorginstituut Nederland. Costing manual: Methodology of
costing research and reference prices for economic evaluations in
healthcare. 2015.
26. Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog
VT, Brouwer WBF. Severity-adjusted probability of being cost effective.
Pharmacoeconomics. 2019;37(9):1155–63. https://doi.org/10.1007/s40273-01
9-00810-8.
27. de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Diepeveen M, van Meerten E,
van Eerden RAG, et al. Concomitant intraperitoneal and systemic
chemotherapy for extensive peritoneal metastases of colorectal origin:
protocol of the multicentre, open-label, phase I, dose-escalation INTERACT
trial. BMJ Open. 2019;9(12):e034508. https://doi.org/10.1136/bmjopen-2019-
034508.
28. Rovers KP, Lurvink RJ, Wassenaar EC, Kootstra TJ, Scholten HJ, Tajzai R, et al.
Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy
(ePIPAC) with oxaliplatin as a palliative monotherapy for isolated
unresectable colorectal peritoneal metastases: protocol of a Dutch,
multicentre, open-label, single-arm, phase II study (CRC-PIPAC). BMJ Open.
2019;9(7):e030408. https://doi.org/10.1136/bmjopen-2019-030408.
29. Tabrizian P, Jayakrishnan TT, Zacharias A, Aycart S, Johnston FM, Sarpel U,
et al. Incorporation of diagnostic laparoscopy in the management algorithm
for patients with peritoneal metastases: a multi-institutional analysis. J Surg
Oncol. 2015;111(8):1035–40. https://doi.org/10.1002/jso.23924.
30. Jayakrishnan TT, Zacharias AJ, Sharma A, Pappas SG, Gamblin TC, Turaga KK.
Role of laparoscopy in patients with peritoneal metastases considered for
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPE
C). World J Surg Oncol. 2014;12(1):270. https://doi.org/10.1186/1477-781
9-12-270.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Engbersen et al. BMC Cancer          (2021) 21:464 Page 8 of 8
